Ha habido 50 transacciones internas recientes registradas para Enanta Pharmaceuticals, Inc. (ENTA), incluyendo 27 compras y 21 ventas. El total de compras internas fue valorado en $13.93M y el total de ventas internas en $378.04K.
Internos destacados con actividad reciente incluyen Carter Bruce L A, Foletta Mark G, Russell Lesley. Las transacciones internas pueden proporcionar información sobre cómo la dirección de la empresa ve la valoración y perspectivas futuras de la acción.
Operaciones de Insiders — ENTA
| Fecha |
Nombre |
Cargo |
Tipo de Transacción |
Acciones |
Precio Promedio |
Valor |
Acciones en Propiedad |
| 2026-03-11 |
Carter Bruce L A |
Director |
Concesión de RSU |
20,000 |
$14.17 |
$283.4K |
20,000 |
| 2026-03-11 |
Foletta Mark G |
Director |
Concesión de RSU |
20,000 |
$14.17 |
$283.4K |
20,000 |
| 2026-03-11 |
Russell Lesley |
Director |
Concesión de RSU |
20,000 |
$14.17 |
$283.4K |
20,000 |
| 2026-03-11 |
Peterson Kristine |
Director |
Concesión de RSU |
20,000 |
$14.17 |
$283.4K |
20,000 |
| 2026-03-11 |
Vance Terry |
Director |
Concesión de RSU |
20,000 |
$14.17 |
$283.4K |
20,000 |
| 2026-03-11 |
Hata Yujiro S |
Director |
Concesión de RSU |
20,000 |
$14.17 |
$283.4K |
20,000 |
| 2026-02-12 |
Luly Jay R. |
President and CEO |
Concesión de RSU |
4,800 |
- |
- |
862,826 |
| 2026-02-12 |
Or Yat Sun |
Chief Scientific Officer |
Concesión de RSU |
1,650 |
- |
- |
373,042 |
| 2026-02-12 |
Kowalsky Matthew Paul |
Chief Legal Officer |
Concesión de RSU |
1,318 |
- |
- |
1,318 |
| 2026-02-12 |
Kieffer Tara Lynn |
Chief Product Strategy Officer |
Concesión de RSU |
1,575 |
- |
- |
32,195 |
| 2026-02-12 |
Luu Brendan |
Chief Business Officer |
Concesión de RSU |
1,575 |
- |
- |
39,904 |
| 2026-02-12 |
Rottinghaus Scott T. |
Chief Medical Officer |
Concesión de RSU |
1,650 |
- |
- |
23,442 |
| 2025-12-05 |
Luly Jay R. |
President and CEO |
Venta Informativa |
4,743 |
$14.23 |
$67.49K |
858,026 |
| 2025-12-05 |
Or Yat Sun |
Chief Scientific Officer |
Venta Informativa |
2,390 |
$14.23 |
$34.01K |
371,392 |
| 2025-12-05 |
Kieffer Tara Lynn |
Chief Product Strategy Officer |
Venta Informativa |
2,106 |
$14.23 |
$29.97K |
30,620 |
| 2025-12-05 |
Luu Brendan |
Chief Business Officer |
Venta Informativa |
1,394 |
$14.23 |
$19.84K |
38,329 |
| 2025-12-05 |
Rottinghaus Scott T. |
Chief Medical Officer |
Venta Informativa |
798 |
$14.23 |
$11.36K |
21,792 |
| 2025-12-05 |
Trout Harry R. Iii |
See Remarks |
Venta Informativa |
542 |
$14.23 |
$7.71K |
16,348 |
| 2025-12-05 |
Capps Kathleen S. |
See Remarks |
Venta Informativa |
323 |
$14.23 |
$4.6K |
8,377 |
| 2025-12-02 |
Trout Harry R. Iii |
See Remarks |
Venta Informativa |
380 |
$13.96 |
$5.3K |
16,890 |
| 2025-12-02 |
Capps Kathleen S. |
See Remarks |
Venta Informativa |
207 |
$13.96 |
$2.89K |
8,700 |
| 2025-12-01 |
Luly Jay R. |
President and CEO |
Retención Fiscal de RSU |
1,885 |
$14.12 |
$26.62K |
862,769 |
| 2025-12-01 |
Or Yat Sun |
Chief Scientific Officer |
Retención Fiscal de RSU |
753 |
$14.12 |
$10.63K |
373,782 |
| 2025-12-01 |
Kieffer Tara Lynn |
Chief Product Strategy Officer |
Retención Fiscal de RSU |
753 |
$14.12 |
$10.63K |
32,726 |
| 2025-12-01 |
Luu Brendan |
Chief Business Officer |
Retención Fiscal de RSU |
498 |
$14.12 |
$7.03K |
39,723 |
| 2025-12-01 |
Trout Harry R. Iii |
See Remarks |
Retención Fiscal de RSU |
105 |
$14.12 |
$1.48K |
17,270 |
| 2025-12-01 |
Capps Kathleen S. |
See Remarks |
Retención Fiscal de RSU |
85 |
$14.12 |
$1.2K |
8,907 |
| 2025-11-25 |
Luly Jay R. |
President and CEO |
Concesión de RSU |
310,000 |
$13.66 |
$4.23M |
310,000 |
| 2025-11-25 |
Or Yat Sun |
Chief Scientific Officer |
Concesión de RSU |
110,000 |
$13.66 |
$1.5M |
110,000 |
| 2025-11-25 |
Kowalsky Matthew Paul |
Chief Legal Officer |
Concesión de RSU |
90,000 |
$13.66 |
$1.23M |
90,000 |
| 2025-11-25 |
Kieffer Tara Lynn |
Chief Product Strategy Officer |
Concesión de RSU |
100,000 |
$13.66 |
$1.37M |
100,000 |
| 2025-11-25 |
Luu Brendan |
Chief Business Officer |
Concesión de RSU |
90,000 |
$13.66 |
$1.23M |
90,000 |
| 2025-11-25 |
Rottinghaus Scott T. |
Chief Medical Officer |
Concesión de RSU |
110,000 |
$13.66 |
$1.5M |
110,000 |
| 2025-11-25 |
Trout Harry R. Iii |
See Remarks |
Concesión de RSU |
12,925 |
$13.66 |
$176.56K |
12,925 |
| 2025-11-25 |
Capps Kathleen S. |
See Remarks |
Concesión de RSU |
6,325 |
$13.66 |
$86.4K |
6,325 |
| 2025-08-26 |
Trout Harry R. Iii |
Vice President, Finance |
Desconocido |
10,000 |
$63.35 |
$633.5K |
- |
| 2025-08-26 |
Capps Kathleen S. |
See Remarks |
Desconocido |
8,125 |
$63.35 |
$514.72K |
- |
| 2025-08-08 |
Rottinghaus Scott T. |
Chief Medical Officer |
Retención Fiscal de RSU |
2,217 |
$6.99 |
$15.5K |
22,590 |
| 2025-03-13 |
Carter Bruce L A |
Director |
Concesión de RSU |
15,700 |
$6.83 |
$107.23K |
15,700 |
| 2025-03-13 |
Foletta Mark G |
Director |
Concesión de RSU |
15,700 |
$6.83 |
$107.23K |
15,700 |
| 2025-03-13 |
Russell Lesley |
Director |
Concesión de RSU |
15,700 |
$6.83 |
$107.23K |
15,700 |
| 2025-03-13 |
Peterson Kristine |
Director |
Concesión de RSU |
15,700 |
$6.83 |
$107.23K |
15,700 |
| 2025-03-13 |
Vance Terry |
Director |
Concesión de RSU |
15,700 |
$6.83 |
$107.23K |
15,700 |
| 2025-03-13 |
Hata Yujiro S |
Director |
Concesión de RSU |
15,700 |
$6.83 |
$107.23K |
15,700 |
| 2025-02-12 |
Luly Jay R. |
President and CEO |
Compra Informativa |
45,000 |
$5.69 |
$256.05K |
846,638 |
| 2025-02-12 |
Mellett Paul J |
Chief Fin. & Admin Officer |
Retención Fiscal de RSU |
3,326 |
$5.59 |
$18.59K |
95,884 |
| 2025-02-12 |
Luly Jay R. |
President and CEO |
Retención Fiscal de RSU |
7,484 |
$5.59 |
$41.84K |
864,654 |
| 2025-02-12 |
Or Yat Sun |
Chief Scientific Officer |
Retención Fiscal de RSU |
4,324 |
$5.59 |
$24.17K |
374,535 |
| 2025-02-12 |
Kieffer Tara Lynn |
Chief Product Strategy Officer |
Retención Fiscal de RSU |
3,326 |
$5.59 |
$18.59K |
33,479 |
| 2025-02-12 |
Luu Brendan |
Chief Business Officer |
Retención Fiscal de RSU |
3,326 |
$5.59 |
$18.59K |
40,221 |
■ Informativa — transacción en mercado abierto (más significativa)
■ No informativa (compra) — premio, ejercicio de opción, conversión
■ No informativa (venta) — retención fiscal, venta de adjudicación
■ Neutral — regalo, fideicomiso, vencimiento
